Point72 Hong Kong LTD Vertex Pharmaceuticals Inc Call Options Transaction History

Point72 Hong Kong LTD

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $1.56 Million - $1.74 Million	5,700 Added 121.28%	10,400 $3.01 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $1.56 Million - $1.74 Million	5,700 Added 121.28%	10,400 $3.01 Million
Q2 2022 Aug 15, 2022	BUY	$234.96 - $292.55 $375,936 - $468,080	1,600 Added 51.61%	4,700 $1.32 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $1.75 Million - $2.21 Million	-9,900 Reduced 76.15%	3,100 $681,000
Q3 2021 Nov 15, 2021	SELL	$181.39 - $202.99 $1.63 Million - $1.83 Million	-9,000 Reduced 40.91%	13,000 $2.36 Million
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $2.92 Million - $3.45 Million	15,600 Added 243.75%	22,000 $4.44 Million
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $1.32 Million - $1.77 Million	6,400 New	6,400 $1.51 Million

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.